189 related articles for article (PubMed ID: 28920433)
1. Fluorotryptophan Incorporation Modulates the Structure and Stability of Transthyretin in a Site-Specific Manner.
Sun X; Dyson HJ; Wright PE
Biochemistry; 2017 Oct; 56(41):5570-5581. PubMed ID: 28920433
[TBL] [Abstract][Full Text] [Related]
2. An engineered transthyretin monomer that is nonamyloidogenic, unless it is partially denatured.
Jiang X; Smith CS; Petrassi HM; Hammarström P; White JT; Sacchettini JC; Kelly JW
Biochemistry; 2001 Sep; 40(38):11442-52. PubMed ID: 11560492
[TBL] [Abstract][Full Text] [Related]
3. NMR Measurements Reveal the Structural Basis of Transthyretin Destabilization by Pathogenic Mutations.
Leach BI; Zhang X; Kelly JW; Dyson HJ; Wright PE
Biochemistry; 2018 Jul; 57(30):4421-4430. PubMed ID: 29972637
[TBL] [Abstract][Full Text] [Related]
4. Quantification of quaternary structure stability in aggregation-prone proteins under physiological conditions: the transthyretin case.
Robinson LZ; Reixach N
Biochemistry; 2014 Oct; 53(41):6496-510. PubMed ID: 25245430
[TBL] [Abstract][Full Text] [Related]
5. Dissecting the structure, thermodynamic stability, and aggregation properties of the A25T transthyretin (A25T-TTR) variant involved in leptomeningeal amyloidosis: identifying protein partners that co-aggregate during A25T-TTR fibrillogenesis in cerebrospinal fluid.
Azevedo EP; Pereira HM; Garratt RC; Kelly JW; Foguel D; Palhano FL
Biochemistry; 2011 Dec; 50(51):11070-83. PubMed ID: 22091638
[TBL] [Abstract][Full Text] [Related]
6. Kinetic analysis of the multistep aggregation pathway of human transthyretin.
Sun X; Dyson HJ; Wright PE
Proc Natl Acad Sci U S A; 2018 Jul; 115(27):E6201-E6208. PubMed ID: 29915031
[TBL] [Abstract][Full Text] [Related]
7. Tolcapone, a potent aggregation inhibitor for the treatment of familial leptomeningeal amyloidosis.
Pinheiro F; Varejão N; Esperante S; Santos J; Velázquez-Campoy A; Reverter D; Pallarès I; Ventura S
FEBS J; 2021 Jan; 288(1):310-324. PubMed ID: 32324953
[TBL] [Abstract][Full Text] [Related]
8. Mispacking of the Phe87 Side Chain Reduces the Kinetic Stability of Human Transthyretin.
Sun X; Jaeger M; Kelly JW; Dyson HJ; Wright PE
Biochemistry; 2018 Dec; 57(51):6919-6922. PubMed ID: 30540442
[TBL] [Abstract][Full Text] [Related]
9. Anion shielding of electrostatic repulsions in transthyretin modulates stability and amyloidosis: insight into the chaotrope unfolding dichotomy.
Hammarström P; Jiang X; Deechongkit S; Kelly JW
Biochemistry; 2001 Sep; 40(38):11453-9. PubMed ID: 11560493
[TBL] [Abstract][Full Text] [Related]
10. Transthyretin variants with improved inhibition of β-amyloid aggregation.
Mangrolia P; Yang DT; Murphy RM
Protein Eng Des Sel; 2016 Jun; 29(6):209-218. PubMed ID: 27099354
[TBL] [Abstract][Full Text] [Related]
11. Effects of Phe-to-Trp mutation and fluorotryptophan incorporation on the solution structure of cardiac troponin C, and analysis of its suitability as a potential probe for in situ NMR studies.
Wang X; Mercier P; Letourneau PJ; Sykes BD
Protein Sci; 2005 Sep; 14(9):2447-60. PubMed ID: 16131667
[TBL] [Abstract][Full Text] [Related]
12. Quantification of the thermodynamically linked quaternary and tertiary structural stabilities of transthyretin and its disease-associated variants: the relationship between stability and amyloidosis.
Hurshman Babbes AR; Powers ET; Kelly JW
Biochemistry; 2008 Jul; 47(26):6969-84. PubMed ID: 18537267
[TBL] [Abstract][Full Text] [Related]
13. Disease-associated mutations impacting BC-loop flexibility trigger long-range transthyretin tetramer destabilization and aggregation.
Esperante SA; Varejāo N; Pinheiro F; Sant'Anna R; Luque-Ortega JR; Alfonso C; Sora V; Papaleo E; Rivas G; Reverter D; Ventura S
J Biol Chem; 2021 Sep; 297(3):101039. PubMed ID: 34343569
[TBL] [Abstract][Full Text] [Related]
14. Comparison of lethal and nonlethal transthyretin variants and their relationship to amyloid disease.
McCutchen SL; Lai Z; Miroy GJ; Kelly JW; Colón W
Biochemistry; 1995 Oct; 34(41):13527-36. PubMed ID: 7577941
[TBL] [Abstract][Full Text] [Related]
15. D18G transthyretin is monomeric, aggregation prone, and not detectable in plasma and cerebrospinal fluid: a prescription for central nervous system amyloidosis?
Hammarström P; Sekijima Y; White JT; Wiseman RL; Lim A; Costello CE; Altland K; Garzuly F; Budka H; Kelly JW
Biochemistry; 2003 Jun; 42(22):6656-63. PubMed ID: 12779320
[TBL] [Abstract][Full Text] [Related]
16. 19F NMR studies of plasminogen activator inhibitor-1.
Abbott GL; Blouse GE; Perron MJ; Shore JD; Luck LA; Szabo AG
Biochemistry; 2004 Feb; 43(6):1507-19. PubMed ID: 14769027
[TBL] [Abstract][Full Text] [Related]
17. Cooperative stabilization of transthyretin by clusterin and diflunisal.
Greene MJ; Klimtchuk ES; Seldin DC; Berk JL; Connors LH
Biochemistry; 2015 Jan; 54(2):268-78. PubMed ID: 25478940
[TBL] [Abstract][Full Text] [Related]
18. The acid-mediated denaturation pathway of transthyretin yields a conformational intermediate that can self-assemble into amyloid.
Lai Z; Colón W; Kelly JW
Biochemistry; 1996 May; 35(20):6470-82. PubMed ID: 8639594
[TBL] [Abstract][Full Text] [Related]
19. Mutation and low pH effect on the stability as well as unfolding kinetics of transthyretin dimer.
Xue Q; Zheng QC; Zhang JL; Cui YL; Chu WT; Zhang HX
Biophys Chem; 2014 May; 189():8-15. PubMed ID: 24632442
[TBL] [Abstract][Full Text] [Related]
20. Thermodynamic Stability and Aggregation Kinetics of EF Helix and EF Loop Variants of Transthyretin.
Ferguson JA; Sun X; Dyson HJ; Wright PE
Biochemistry; 2021 Mar; 60(10):756-764. PubMed ID: 33645214
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
